NAPLEX Quiz: Medication Use Evaluation

What this quiz covers

This quiz focuses on Medication Use Evaluation, giving you a quick way to practice the rules, question types, and explanations that matter most for NAPLEX.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

Question 1

1. Substitute pantoprazole 40 mg PO daily as a therapeutically equivalent formulary proton pump inhibitor (correct answer)
2. Switch to famotidine 10 mg PO daily because it is over-the-counter and always equivalent to a PPI for erosive disease
3. Change to omeprazole 10 mg PO daily because all PPIs are interchangeable at any dose
4. Discontinue acid suppression entirely because long-term PPIs should never be used beyond 4 weeks

Explanation: This question evaluates therapeutic interchange skills within formulary management for proton pump inhibitors. The key patient-specific factor is a stable patient on esomeprazole 40 mg daily for erosive esophagitis who requires conversion to an available formulary agent while maintaining therapeutic efficacy. Option A is correct because pantoprazole 40 mg daily provides equivalent acid suppression to esomeprazole 40 mg for erosive esophagitis, as all PPIs at standard doses achieve similar healing rates and symptom control when used appropriately. Option B incorrectly suggests famotidine 10 mg, which is an H2-receptor antagonist that provides inferior acid suppression compared to PPIs and is inadequate for erosive disease maintenance. Option C suggests an inadequate dose conversion, as omeprazole 10 mg is a half-standard dose and not equivalent to esomeprazole 40 mg for erosive disease. Option D inappropriately recommends discontinuing therapy in a patient with documented erosive disease who may require long-term maintenance to prevent complications. The clinical framework is that PPIs can be interchanged at equipotent doses: esomeprazole 40 mg = pantoprazole 40 mg = omeprazole 40 mg = lansoprazole 30 mg = rabeprazole 20 mg for erosive GERD maintenance.

Question 2

1. Continue simvastatin 20 mg nightly along with atorvastatin 80 mg daily to maximize LDL lowering after TIA
2. Stop simvastatin and use atorvastatin 80 mg daily as the single statin; confirm intended antiplatelet plan and provide clear written instructions to avoid duplicate therapy (correct answer)
3. Stop clopidogrel because aspirin was already used before admission and dual therapy is never indicated after TIA
4. Stop atorvastatin and restart simvastatin 20 mg nightly because the patient was stable on it prior to admission

Explanation: This question evaluates medication reconciliation skills focusing on therapeutic duplication and guideline-directed therapy optimization. The key patient-specific factor is discharge after TIA with two different statins prescribed (simvastatin 20 mg and atorvastatin 80 mg) plus the patient's intention to continue all medications including duplicates. Option B correctly identifies that high-intensity statin therapy (atorvastatin 80 mg) is guideline-recommended after TIA/stroke, making continuation of both statins inappropriate and potentially harmful due to increased myopathy risk without additional benefit. Option A dangerously suggests continuing dual statin therapy, which provides no additional LDL reduction beyond monotherapy while significantly increasing adverse effect risk. Option C incorrectly suggests stopping clopidogrel when short-term dual antiplatelet therapy (aspirin plus clopidogrel for 21-90 days) may be appropriate after minor stroke/TIA per current guidelines. Option D inappropriately returns to moderate-intensity statin therapy when high-intensity therapy is indicated for secondary prevention after cerebrovascular events. The clinical framework is that medication reconciliation must identify and resolve therapeutic duplications while ensuring patients receive guideline-directed intensity of therapy, with clear communication about which medications to stop and continue.

Question 3

1. Continue glyburide and add sitagliptin 100 mg PO daily to reduce glucose variability
2. Discontinue glyburide and transition to a lower hypoglycemia-risk agent (e.g., linagliptin 5 mg PO daily), with relaxed glycemic targets and follow-up glucose monitoring (correct answer)
3. Increase glyburide to 15 mg PO twice daily because A1c is below 7% and tighter control is preferred in older adults
4. Maintain current therapy and monitor only A1c every 12 months because hypoglycemia is expected with good control

Explanation: This question tests recognition and management of medication-induced hypoglycemia in vulnerable populations. The critical patient-specific factors are an older adult (79 years) with CKD stage 3b (eGFR 28) experiencing recurrent hypoglycemia (glucose 48-62 mg/dL) while taking glyburide, a long-acting sulfonylurea contraindicated in severe renal impairment. Option B is the best approach because glyburide accumulates in renal dysfunction and causes prolonged hypoglycemia in older adults; switching to a DPP-4 inhibitor like linagliptin (no renal adjustment needed) with relaxed glycemic targets (A1c 7-8%) reduces hypoglycemia risk while maintaining appropriate control. Option A inappropriately adds another glucose-lowering agent when the patient is already experiencing hypoglycemia with an A1c below individualized goals. Option C dangerously suggests increasing glyburide, which would worsen hypoglycemia risk, and incorrectly states that tighter control is preferred in older adults when guidelines recommend relaxation of targets. Option D fails to address a serious safety issue, as recurrent hypoglycemia in older adults increases fall risk, cognitive decline, and cardiovascular events. The clinical pearl is that glyburide should be avoided in patients over 65 years or with CKD due to prolonged half-life and hypoglycemia risk, with newer agents providing safer alternatives.

Question 4

1. Additive central nervous system depression from high-dose gabapentin (with dose stacking) combined with diphenhydramine, worsened by reduced renal clearance (correct answer)
2. Metformin-induced hypoglycemia due to taking metformin with meals
3. Lisinopril-induced hepatotoxicity causing dizziness, supported by normal liver function tests
4. Diabetic ketoacidosis because A1c is above goal

Explanation: This question tests adverse effect identification in the context of inappropriate dosing and drug combinations in chronic kidney disease. The key patient-specific factors are gabapentin 900 mg three times daily (often taken all at once) in a patient with eGFR 42 mL/min/1.73 m², combined with nightly diphenhydramine use, presenting with sedation, dizziness, and falls. Option A correctly identifies that gabapentin requires dose reduction in CKD stage 3a (typical max 300-600 mg three times daily), and taking all doses together creates dose stacking with prolonged CNS depression, which is potentiated by the anticholinergic effects of diphenhydramine. Option B is incorrect because metformin doesn't cause hypoglycemia as monotherapy, and taking it with meals is the correct administration method. Option C is implausible as lisinopril rarely causes hepatotoxicity, and the normal liver enzymes contradict this mechanism. Option D is incorrect because the A1c of 7.4% and absence of typical DKA symptoms (no mention of acidosis, ketones, or severe hyperglycemia) make this diagnosis impossible. The clinical pearl is that gabapentin accumulates in renal dysfunction and requires dose adjustment based on eGFR, while concurrent CNS depressants multiply the risk of sedation and falls in older adults.

Question 5

1. Continue lisinopril because renal function and potassium are normal, and re-evaluate after the first trimester
2. Discontinue lisinopril and contact the prescriber to switch to a pregnancy-preferred agent such as labetalol or nifedipine ER; counsel on fetal risk and document the intervention (correct answer)
3. Increase lisinopril to 20 mg PO daily to reach the blood pressure goal more quickly
4. Add spironolactone 25 mg PO daily to lisinopril to improve blood pressure control during pregnancy

Explanation: This question tests medication safety knowledge regarding teratogenic drugs in pregnancy. The critical patient-specific factor is a 10-week pregnant woman taking lisinopril, an ACE inhibitor with well-documented teratogenic effects including renal dysgenesis, oligohydramnios, and fetal growth restriction, particularly in the second and third trimesters. Option B is the best response because immediate discontinuation of lisinopril is essential to minimize fetal exposure, with transition to pregnancy-preferred agents like labetalol or nifedipine ER that effectively control blood pressure without teratogenic risk. Option A dangerously suggests continuing a known teratogen through the critical period of organogenesis and into the second trimester when renal effects become most pronounced. Option C inappropriately suggests increasing the dose of a teratogenic medication, compounding the fetal risk. Option D suggests adding spironolactone, another medication contraindicated in pregnancy due to anti-androgenic effects, creating double teratogenic exposure. The clinical pearl is that ACE inhibitors and ARBs must be discontinued immediately upon pregnancy recognition, with methyldopa, labetalol, and long-acting nifedipine being first-line alternatives for chronic hypertension in pregnancy.

Question 6

1. Switch to pantoprazole 40 mg by mouth daily as a therapeutically equivalent PPI alternative (correct answer)
2. Switch to famotidine 10 mg by mouth daily because it is preferred on most formularies
3. Stop PPI therapy abruptly and use calcium carbonate as needed only
4. Switch to omeprazole 10 mg by mouth daily regardless of prior erosive disease severity

Explanation: This question tests medication use evaluation for therapeutic substitution in GERD management under formulary constraints. The key patient-specific factors are history of erosive esophagitis requiring high-dose PPI for healing, current symptom control with esomeprazole 40 mg, and formulary preference for omeprazole or pantoprazole. Switching to pantoprazole 40 mg daily is the best choice as it provides equivalent potency and efficacy for erosive disease at a cost-effective dose. Switching to famotidine 10 mg is suboptimal due to lower efficacy for erosive esophagitis compared to PPIs; stopping PPI abruptly risks rebound symptoms; omeprazole 10 mg is underdosed for maintenance in erosive cases. A clinical pearl is that PPIs like pantoprazole and omeprazole are therapeutically interchangeable at equipotent doses (e.g., 40 mg). In similar scenarios, confirm disease severity, match doses for equivalence, and monitor symptoms post-substitution.

Question 7

1. Advise applying two 21 mg patches daily to compensate for missed days
2. Recommend setting a daily morning reminder, linking patch application to a routine, and considering combination NRT (patch plus gum/lozenge) with counseling (correct answer)
3. Stop nicotine replacement immediately because vivid dreams indicate allergy
4. Switch bupropion SR to bupropion XL 450 mg daily to eliminate cravings without monitoring

Explanation: This question tests medication use evaluation for improving adherence in smoking cessation therapy. The key patient-specific factors are ongoing smoking (10 cigarettes/day), intermittent nicotine patch use, vivid dreams, and bupropion for depression, with a goal of complete cessation. Recommending daily reminders, routine linking, and combination NRT with counseling is the best choice to boost adherence and efficacy through behavioral support and additional nicotine delivery. Applying two patches compensates incorrectly and risks overdose; stopping NRT ignores benefits; switching to bupropion XL 450 mg exceeds dosing limits. A clinical pearl is that combination NRT (patch + short-acting) doubles quit rates; address barriers holistically. In similar scenarios, assess usage patterns, add motivational interviewing, and monitor progress with carbon monoxide levels.

Question 8

1. Recommend using albuterol on a fixed schedule twice daily and using budesonide-formoterol only when symptomatic
2. Provide inhaler technique teach-back and a written action plan distinguishing daily controller use from rescue use, and synchronize refills (correct answer)
3. Discontinue budesonide-formoterol and continue montelukast alone to reduce medication burden
4. Advise the patient to stop prednisone early once breathing improves to minimize side effects and improve adherence

Explanation: This question tests medication use evaluation for improving adherence and education in asthma management during transitions of care. The key patient-specific factors are confusion between controller (budesonide-formoterol) and rescue (albuterol) inhalers, poor pre-admission adherence, and outdated refills indicating nonadherence. Providing inhaler technique teach-back, a written action plan, and refill synchronization is the best choice to clarify roles, enhance understanding, and prevent readmissions by ensuring consistent controller use. Using albuterol on a fixed schedule with symptomatic budesonide-formoterol misaligns with guidelines favoring daily controllers; discontinuing budesonide-formoterol ignores the need for maintenance therapy; stopping prednisone early risks rebound exacerbation. A clinical pearl is to distinguish controllers for daily prevention from rescuers for acute relief in action plans. In similar scenarios, perform thorough reconciliation, assess barriers via teach-back, and implement reminders or synchronization for chronic therapies.

Question 9

1. Increase gabapentin to 900 mg three times daily to overcome tolerance
2. Reduce gabapentin dose and/or frequency based on renal function and reassess pain and sedation at follow-up (correct answer)
3. Continue gabapentin unchanged and add diphenhydramine at bedtime to improve sleep quality
4. Switch gabapentin to pregabalin at an equivalent high dose without renal adjustment

Explanation: This question tests the concept of medication use evaluation (MUE) focused on renal dose adjustments for medications in patients with chronic kidney disease to optimize safety and efficacy. The key patient-specific factor is the patient's reduced creatinine clearance of 28 mL/min, which impairs gabapentin clearance, leading to accumulation and adverse effects like dizziness and sedation at the current dose of 600 mg three times daily. Reducing the gabapentin dose and/or frequency based on renal function is the best choice as it minimizes adverse effects while maintaining pain control, with reassessment at follow-up to ensure therapeutic outcomes. Increasing the dose to 900 mg three times daily is incorrect as it would exacerbate accumulation and side effects without addressing tolerance, which is not typically an issue with gabapentin; continuing unchanged and adding diphenhydramine would worsen sedation and anticholinergic burden. Switching to pregabalin without renal adjustment is suboptimal because pregabalin also requires dose reduction in renal impairment, potentially leading to similar toxicity. A key clinical pearl is that for renally cleared drugs like gabapentin, always calculate estimated creatinine clearance using tools like Cockcroft-Gault and adjust doses per guidelines to prevent adverse events. In similar scenarios, prioritize dose optimization over adding new agents, incorporating patient-reported outcomes like sedation into decision-making frameworks for holistic care.

Question 10

1. Increase hydrochlorothiazide to 50 mg PO daily to improve blood pressure and accept the uric acid elevation
2. Switch hydrochlorothiazide to losartan 50 mg PO daily and titrate as needed while continuing amlodipine (correct answer)
3. Stop amlodipine and start propranolol 40 mg PO twice daily as monotherapy to reduce gout risk
4. Add indomethacin 50 mg PO three times daily chronically to prevent gout flares while keeping the antihypertensive regimen unchanged

Explanation: This question evaluates medication optimization when a drug contributes to both therapeutic failure and adverse effects. The key patient-specific factors are uncontrolled hypertension (152/94 mmHg) despite dual therapy, recurrent gout flares (2 in 3 months), and elevated uric acid (9.2 mg/dL) likely worsened by hydrochlorothiazide. Option B is the best choice because losartan uniquely provides antihypertensive efficacy while possessing mild uricosuric properties that can lower uric acid levels, addressing both the blood pressure gap and reducing gout risk. Option A inappropriately increases the thiazide dose, which would further elevate uric acid and potentially worsen gout frequency despite possible blood pressure improvement. Option C incorrectly suggests propranolol monotherapy, which is insufficient for the degree of hypertension and has no beneficial effect on uric acid levels. Option D dangerously recommends chronic NSAID use in a hypertensive patient, which would worsen blood pressure control, increase cardiovascular risk, and potentially cause renal dysfunction. The clinical framework is that when thiazide diuretics exacerbate gout in hypertensive patients, switching to losartan provides dual benefit through blood pressure reduction and uric acid lowering via increased renal urate excretion.

Question 11

1. Provide brief counseling only and keep the current regimen unchanged because the controller is already prescribed
2. Switch to a once-daily controller option if appropriate (e.g., fluticasone furoate/vilanterol 100/25 mcg 1 inhalation daily), assess inhaler technique, and schedule a 2–4 week follow-up to review symptom and refill data (correct answer)
3. Discontinue the inhaled corticosteroid/long-acting beta-agonist and increase albuterol to scheduled use four times daily
4. Add montelukast 10 mg nightly but do not assess inhaler technique or refill history because symptoms alone determine adherence

Explanation: This question evaluates medication use optimization for improving asthma control through adherence interventions. The key patient-specific factor is documented poor adherence to twice-daily controller therapy (fills every 60 days instead of 30, admits missing evening doses) resulting in poor asthma control evidenced by excessive rescue inhaler use (3 inhalers/month), frequent nighttime symptoms, and exacerbations requiring oral steroids. Option B is the best strategy because switching to a once-daily controller regimen addresses the primary adherence barrier (twice-daily dosing), while technique assessment ensures proper drug delivery, and short-term follow-up allows objective assessment of improvement through refill and symptom data. Option A fails to address the identified adherence problem and misses the opportunity to optimize therapy when the patient is experiencing poor control. Option C dangerously suggests discontinuing controller therapy and using short-acting bronchodilators scheduled, which would worsen asthma control and increase exacerbation risk. Option D adds medication without addressing the primary adherence issue and incorrectly dismisses the value of objective refill data in assessing adherence. The clinical framework is that simplifying controller regimens to once-daily options improves adherence rates by 20-30% compared to twice-daily regimens, with adherence being the most modifiable factor in achieving asthma control.

Question 12

1. Continue diphenhydramine and oxybutynin as scheduled because they are long-standing therapies
2. Discontinue diphenhydramine for sleep and recommend nonpharmacologic sleep measures; reassess need for oxybutynin due to anticholinergic effects (correct answer)
3. Increase diphenhydramine to 75 mg nightly to improve sleep quality and reduce nighttime wandering
4. Add amitriptyline 25 mg nightly to improve sleep and mood

Explanation: This question tests medication use evaluation for reducing anticholinergic burden in elderly patients during care transitions. The key patient-specific factors are altered mental status, falls, and high anticholinergic load from diphenhydramine and oxybutynin, both contributing to cognitive and mobility risks. Discontinuing diphenhydramine with nonpharmacologic sleep measures and reassessing oxybutynin is the best choice to lower burden, improve safety, and address fall risk. Continuing both ignores guidelines like Beers Criteria; increasing diphenhydramine worsens effects; adding amitriptyline adds more anticholinergics. A clinical pearl is that anticholinergic drugs increase delirium and fall risk in older adults; prioritize deprescribing. In similar scenarios, calculate anticholinergic burden scores, target high-risk agents first, and substitute with safer alternatives or non-drug options.

Question 13

1. Continue current regimen without changes and recheck SCr at the end of therapy
2. Recommend discontinuing piperacillin-tazobactam if not needed and optimizing vancomycin dosing using AUC-guided adjustments while avoiding NSAIDs (correct answer)
3. Increase vancomycin dose to achieve higher exposure since bacteremia is severe, regardless of rising SCr
4. Add gentamicin for synergy and continue NSAIDs for pain control to improve comfort

Explanation: This question tests medication use evaluation for mitigating nephrotoxicity in antibiotic regimens. The key patient-specific factors are rising SCr (0.9 to 1.6 mg/dL), decreasing urine output, high vancomycin AUC, and concurrent piperacillin-tazobactam and ibuprofen, all nephrotoxic. Recommending discontinuation of unnecessary agents, AUC-guided vancomycin adjustments, and avoiding NSAIDs is the best choice to protect kidneys while treating MRSA. Continuing without changes risks further injury; increasing vancomycin ignores toxicity; adding gentamicin adds more nephrotoxicity. A clinical pearl is that vancomycin plus piperacillin-tazobactam synergistically increases AKI risk; monitor SCr daily. In similar scenarios, identify culprits (e.g., calculate vancomycin AUC via levels), prioritize de-escalation, and select alternatives like acetaminophen for pain.

Question 14

1. Recommend increasing albuterol use to 2 puffs four times daily on a scheduled basis
2. Provide counseling that inhaled corticosteroid is a daily controller, assess barriers, and use refill reminders with a follow-up check-in in 2–4 weeks (correct answer)
3. Stop fluticasone because daily symptoms indicate it is ineffective, and use albuterol alone
4. Switch cetirizine to diphenhydramine nightly to improve asthma control through sedation

Explanation: This question tests medication use evaluation for promoting adherence to asthma controller medications. The key patient-specific factors are persistent symptoms (nighttime awakenings, daily albuterol use), suboptimal peak flow (320 vs. 450 L/min), and misuse of fluticasone as 'when needed' instead of daily. Counseling on controller role, assessing barriers, and using reminders with follow-up is the best choice to ensure consistent use and improve control. Increasing albuterol to scheduled use promotes overuse and masks poor control; stopping fluticasone leaves inflammation untreated; switching cetirizine to diphenhydramine adds unnecessary sedation. A clinical pearl is that inhaled corticosteroids are daily preventives, not rescuers; adherence improves with education. In similar scenarios, review symptoms and refill history, educate via teach-back, and implement monitoring like peak flow logs for adjustments.

Question 15

1. Switch apixaban to rivaroxaban 20 mg by mouth once daily to simplify dosing and improve adherence
2. Continue apixaban 5 mg by mouth twice daily and add aspirin 81 mg daily for additional stroke prevention
3. Reduce apixaban to 2.5 mg by mouth twice daily due to renal impairment and interacting diltiazem (correct answer)
4. Hold apixaban and start warfarin 10 mg by mouth daily without INR monitoring until follow-up

Explanation: This question tests medication use evaluation for appropriate dosing of direct oral anticoagulants in patients with atrial fibrillation and comorbidities. The key patient-specific factors are the patient's age of 78 years, weight of 58 kg, serum creatinine of 1.7 mg/dL (estimated CrCl 25 mL/min), and concurrent use of diltiazem, a moderate CYP3A4 and P-gp inhibitor that increases apixaban exposure. Reducing apixaban to 2.5 mg twice daily is the best choice because the patient meets two criteria for dose reduction (weight ≤60 kg and SCr ≥1.5 mg/dL), and diltiazem further necessitates caution to minimize bleeding risk while maintaining efficacy. Switching to rivaroxaban 20 mg daily is incorrect as the appropriate dose for CrCl 15-50 mL/min is 15 mg daily, not 20 mg, and it does not address adherence; adding aspirin increases bleeding without added benefit in nonvalvular AF; starting warfarin 10 mg without INR monitoring risks supratherapeutic effects and bleeding. Holding apixaban abruptly and initiating warfarin without bridging or monitoring is unsafe given the patient's stability on apixaban. A clinical pearl is that apixaban dose reduction criteria should be assessed independently, with additional consideration for drug interactions; always calculate CrCl using Cockcroft-Gault for renal dosing. In similar scenarios, prioritize bleeding risk minimization by verifying dose adjustments step-by-step: confirm indication, evaluate renal function, check for interacting drugs, and monitor adherence.

Question 16

1. Add lisinopril 10 mg by mouth daily and titrate as tolerated for BP and albuminuria reduction (correct answer)
2. Discontinue hydrochlorothiazide and start clonidine 0.3 mg patch weekly as first-line therapy
3. Add ibuprofen 600 mg three times daily to reduce vascular inflammation and lower BP
4. Switch amlodipine to immediate-release nifedipine 10 mg three times daily for faster BP control

Explanation: This question tests medication use evaluation for optimizing hypertension therapy in diabetic patients with albuminuria. The key patient-specific factors are uncontrolled BP (154/92 mmHg, goal <130/80), elevated albumin-to-creatinine ratio (120 mg/g), and diabetes, with stable renal function (eGFR 65 mL/min/1.73 m²). Adding lisinopril with titration is the best choice as ACE inhibitors reduce BP and albuminuria, providing renal protection. Discontinuing hydrochlorothiazide for clonidine ignores first-line options; adding ibuprofen risks renal injury; switching to immediate-release nifedipine lacks sustained control. A clinical pearl is that ACE inhibitors are preferred in diabetic hypertension with proteinuria for dual benefits. In similar scenarios, assess BP against guidelines, add renoprotective agents stepwise, and monitor potassium and renal function during titration.

Question 17

1. Continue citalopram and ondansetron as ordered and monitor QTc annually
2. Recommend correcting electrolytes, limiting QT-prolonging agents (e.g., reduce citalopram dose or change antidepressant and use alternative antiemetic), and repeat ECG (correct answer)
3. Increase ondansetron to 16 mg every 8 hours to reduce nausea-related stress on the heart
4. Add azithromycin for nausea because it is well tolerated with SSRIs

Explanation: This question tests medication use evaluation for addressing QT-prolonging drug interactions. The key patient-specific factors are prolonged QTc (510 ms), low potassium (3.2 mEq/L) and magnesium (1.6 mg/dL), and multiple QT-prolongers (citalopram, ondansetron, hydrochlorothiazide). Recommending electrolyte correction, reducing QT agents (e.g., lower citalopram or alternatives), and repeat ECG is the best choice to minimize torsades risk while controlling symptoms. Continuing without changes ignores arrhythmia risk; increasing ondansetron worsens QT prolongation; adding azithromycin adds another QT-prolonger. A clinical pearl is to use CredibleMeds for QT risk assessment and correct modifiable factors first. In similar scenarios, review ECG and electrolytes, prioritize deprescribing high-risk drugs, and monitor QTc serially.

Question 18

1. Continue omeprazole indefinitely because age alone increases ulcer risk
2. Taper and discontinue omeprazole with a plan for on-demand therapy if symptoms recur and monitor for rebound symptoms (correct answer)
3. Increase omeprazole to 40 mg daily to prevent fractures by improving calcium absorption
4. Switch omeprazole to ranitidine 150 mg twice daily without assessing current availability or safety considerations

Explanation: This question tests medication use evaluation for deprescribing unnecessary chronic PPIs in elderly patients. The key patient-specific factors are long-term omeprazole use without current GERD symptoms, osteoporosis, and borderline vitamin B12 (260 pg/mL), with risks like fractures and deficiencies from prolonged PPI. Tapering and discontinuing with on-demand plan and rebound monitoring is the best choice to minimize exposure while preventing symptoms. Continuing indefinitely ignores risks; increasing dose lacks indication; switching to ranitidine is obsolete due to safety recalls. A clinical pearl is to reassess PPI need after 8-12 weeks; taper over 2-4 weeks to avoid rebound. In similar scenarios, evaluate indication and duration, monitor for adverse effects like bone density, and use H2 blockers or antacids as step-down.

Question 19

1. Continue simvastatin 40 mg nightly and add coenzyme Q10 200 mg daily to manage symptoms
2. Discontinue simvastatin and switch to pravastatin 40 mg nightly after symptoms resolve (correct answer)
3. Increase simvastatin to 80 mg nightly to achieve better LDL lowering
4. Continue simvastatin and stop amlodipine to eliminate the interaction without changing lipid therapy

Explanation: This question tests medication use evaluation for managing statin-induced myopathy and drug interactions in hyperlipidemia. The key patient-specific factors are new muscle pain, elevated CK (980 U/L) and liver enzymes, and the interaction between simvastatin 40 mg and amlodipine, which increases simvastatin exposure and myopathy risk. Discontinuing simvastatin and switching to pravastatin 40 mg after resolution is the best choice as pravastatin is not significantly affected by amlodipine and provides equivalent LDL lowering with lower myopathy risk. Continuing simvastatin with coenzyme Q10 lacks strong evidence for symptom relief and ignores the interaction; increasing to simvastatin 80 mg would worsen myopathy; stopping amlodipine eliminates the interaction but may compromise blood pressure control without alternatives. A clinical pearl is that simvastatin doses should be limited to 20 mg with amlodipine per guidelines. In similar scenarios, assess symptoms and labs, identify interactions, and select alternative statins like pravastatin or rosuvastatin, monitoring CK and symptoms post-switch.

Question 20

1. Recommend dispensing oxycodone as written and adding diphenhydramine for sleep to improve comfort
2. Recommend limiting opioid quantity/duration, counsel on avoiding concurrent benzodiazepine use when taking opioids, and offer naloxone per protocol (correct answer)
3. Increase oxycodone to 10 mg every 4 hours as needed to prevent breakthrough pain and reduce anxiety
4. Stop acetaminophen to avoid hepatotoxicity and rely on oxycodone alone for pain control

Explanation: This question tests medication use evaluation for opioid stewardship and interaction management at discharge. The key patient-specific factors are post-surgical opioid prescription with concurrent clonazepam (a benzodiazepine), increasing overdose risk, and low pain (3/10). Recommending limited opioid quantity, counseling against concurrent use, and offering naloxone is the best choice to align with safe practices and reduce harm. Dispensing as written with diphenhydramine adds sedation; increasing oxycodone escalates risk; stopping acetaminophen limits multimodal pain control. A clinical pearl is that opioids plus benzodiazepines amplify respiratory depression; limit to <50 MME/day post-op. In similar scenarios, calculate MME, assess interactions, provide education and naloxone, and follow up on usage.